The Broad Institute, Inc Patent Portfolio Statistics

The Broad Institute, Inc.

Profile Summary

This article summarizes the perfomance of the assignee in the recent years. The overall statistics for this portfolio help to analyze the areas where the assignee is performing well. The filing trend, perfomance across the tech centers and the perfomance of the recent applications has been mentioned below. All the stats are calculated based on the perfomance in USPTO.

How does the overall patent portfolio of The Broad Institute, Inc. look like?

Total Applications: 528
Granted Patents: 151
Grant Index 69.59 %
Abandoned/Rejected Applications: 66 (30.41%)
In-Process Applications: 304
Average Grant Time: 2.86 Years
Average Office Actions: 2.17

Which Technology Area The Broad Institute, Inc. is filing most patents in? (Last 10 years)

Art Unit Definition Total Applications
Opap Parked GAU 119
1636 Molecular Biology, Bioinformatics, Nucleic Acids, Recombinant DNA and RNA, Gene Regulation, Nucleic Acid Amplification, Animals and Plants, Combinatorial/ Computational Chemistry 77
1634 Molecular Biology, Bioinformatics, Nucleic Acids, Recombinant DNA and RNA, Gene Regulation, Nucleic Acid Amplification, Animals and Plants, Combinatorial/ Computational Chemistry 37
1639 Molecular Biology, Bioinformatics, Nucleic Acids, Recombinant DNA and RNA, Gene Regulation, Nucleic Acid Amplification, Animals and Plants, Combinatorial/ Computational Chemistry 21
1637 Molecular Biology, Bioinformatics, Nucleic Acids, Recombinant DNA and RNA, Gene Regulation, Nucleic Acid Amplification, Animals and Plants, Combinatorial/ Computational Chemistry 18

How many patents are The Broad Institute, Inc. filing every year?

Year Total Applications
2022 0*
2021 70*
2020 92
2019 90
2018 60

*The drop in the number of applications filed in last two years compared to previous years is because applications can take up to 18 months to get published

Recently filed patent applications of The Broad Institute, Inc. in USPTO?

Publication number: US20210386829A1
Application number: 17/052,873

Abstract:
The present invention provides novel compositions and methods based on the discovery of the mechanisms and gene expression programs associated with homeostatic ILC2s and proinflammatory ILC2s that drive tissue inflammation. Molecular cues were identified that modulate ILC responses to alarmins using single-cell RNA-sequencing (scRNA-seq) profiles of lung-resident ILCs at steady state and after in vivo stimulation. The neuropeptide CGRP and the CGRP receptor were identified as expressed on ILC2s. Treatment with CGRP reduces allergic lung inflammation and reduces the proliferation and expansion of ILC2 cells. The results demonstrate that CGRP signaling strongly modulates ILC2 responses and highlights the importance of neuro-immune crosstalk in allergic inflammatory responses at mucosal surfaces.

Publication date: 2021-12-16
Applicant: The Broad Institute, Inc.
Inventors: Aviv Regev


Publication number: US20220017938A1
Application number: 17/496,578

Abstract:
In one aspect, the invention features a method for identifying a drug-modulated polypeptide substrate of cereblon (CRBN). In another aspect, the invention features a method of identifying a polypeptide target of a modulator of CRBN. In yet another aspect, the invention provides methods of monitoring or characterizing the sensitivity of a subject to a modulator of CRBN.

Publication date: 2022-01-20
Applicant: The Broad Institute, Inc.
Inventors: Mikkelsen Tarjei


Publication number: US20220023233A1
Application number: 17/494,830

Abstract:
The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of proteinopathies, particularly MUC1-associated kidney disease (ADTKD-MUC1 or MKD), Retinitis Pigmentosa (e.g., due to rhodopsin mutations), autosomal dominant tubulo-interstitial kidney disease due to UMOD mutation(s) (ADTKD-UMOD), and other forms of toxic proteinopathies resulting from mutant protein accumulation in the ER or other secretory pathway compartments and/or vesicles, among others. The disclosure also identifies and provides TMED9-binding agents as capable of treating or preventing proteinopathies of the secretory pathway, and further provides methods for identifying additional TMED9-binding agents.

Publication date: 2022-01-27
Applicant: The Broad Institute, Inc.
Inventors: Eric Lander


How are The Broad Institute, Inc.’s applications performing in USPTO?

Application Number Title Status Art Unit Examiner
17/052,873 Compositions And Methods For Modulating Cgrp Signaling To Regulate Innate Lymphoid Cell Inflammatory Responses Application Returned back to Preexam OPAP Central, Docket
17/496,578 Methods Of Identifying Drug-Modulated Polypeptide Targets For Degradation OPAP Central, Docket
17/494,830 Agents For Reversing Toxic Proteinopathies OPAP Central, Docket
17/495,219 Crispr Effector System Based Diagnostics 1636
17/489,308 Protected Guide Rnas (Pgrnas) OPAP Central, Docket